Summary
Global Markets Direct’s, ‘Rhinovirus Infection - Pipeline Review, H1 2016’, provides an overview of the Rhinovirus Infection pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Rhinovirus Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhinovirus Infection and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Rhinovirus Infection
- The report reviews pipeline therapeutics for Rhinovirus Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rhinovirus Infection therapeutics and enlists all their major and minor projects
- The report assesses Rhinovirus Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rhinovirus Infection
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AIMM Therapeutics B.V.
Biological Mimetics, Inc.
Biota Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Johnson & Johnson
Novartis AG
Theraclone Sciences, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rhinovirus Infection Overview 7
Therapeutics Development 8
Pipeline Products for Rhinovirus Infection - Overview 8
Pipeline Products for Rhinovirus Infection - Comparative Analysis 9
Rhinovirus Infection - Therapeutics under Development by Companies 10
Rhinovirus Infection - Therapeutics under Investigation by Universities/Institutes 11
Rhinovirus Infection - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Rhinovirus Infection - Products under Development by Companies 14
Rhinovirus Infection - Products under Investigation by Universities/Institutes 15
Rhinovirus Infection - Companies Involved in Therapeutics Development 16
AIMM Therapeutics B.V. 16
Biological Mimetics, Inc. 17
Biota Pharmaceuticals, Inc. 18
Boehringer Ingelheim GmbH 19
Johnson & Johnson 20
Novartis AG 21
Theraclone Sciences, Inc. 22
Rhinovirus Infection - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
BNT-014 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
KR-22809 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibodies for Human Rhinovirus Infections - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody for Asthma, COPD and Rhinovirus Infections - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
OBR-5340 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PL-402 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Recombinant Peptide for Rhinovirus Infection - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules for Rhinovirus Infections - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit RNA Polymerase for Rhinovirus and Picornaviridae Infections - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
vapendavir - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Rhinovirus Infection - Recent Pipeline Updates 46
Rhinovirus Infection - Dormant Projects 48
Rhinovirus Infection - Product Development Milestones 49
Featured News & Press Releases 49
Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial 49
Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52
List of Tables
Number of Products under Development for Rhinovirus Infection, H1 2016 8
Number of Products under Development for Rhinovirus Infection - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Rhinovirus Infection - Pipeline by AIMM Therapeutics B.V., H1 2016 16
Rhinovirus Infection - Pipeline by Biological Mimetics, Inc., H1 2016 17
Rhinovirus Infection - Pipeline by Biota Pharmaceuticals, Inc., H1 2016 18
Rhinovirus Infection - Pipeline by Boehringer Ingelheim GmbH, H1 2016 19
Rhinovirus Infection - Pipeline by Johnson & Johnson, H1 2016 20
Rhinovirus Infection - Pipeline by Novartis AG, H1 2016 21
Rhinovirus Infection - Pipeline by Theraclone Sciences, Inc., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Rhinovirus Infection Therapeutics - Recent Pipeline Updates, H1 2016 46
Rhinovirus Infection - Dormant Projects, H1 2016 48
List of Figures
Number of Products under Development for Rhinovirus Infection, H1 2016 8
Number of Products under Development for Rhinovirus Infection - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Targets, H1 2016 24
Number of Products by Stage and Targets, H1 2016 24
Number of Products by Mechanism of Actions, H1 2016 26
Number of Products by Stage and Mechanism of Actions, H1 2016 26
Number of Products by Routes of Administration, H1 2016 28
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Molecule Types, H1 2016 30
Number of Products by Stage and Molecule Types, H1 2016 30
